Quoin Pharmaceuticals, Ltd.
NASDAQ Capital MarketTotal Valuation
Quoin Pharmaceuticals, Ltd. carries a market capitalization of 8.21M, placing it among publicly traded companies globally.
| Market Cap | 8.21M |
| Enterprise Value | N/A |
Share Statistics
Quoin Pharmaceuticals, Ltd. currently has 70.29M shares outstanding.
| Shares Outstanding | 70.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 86.51 |
| P/TBV Ratio | 94.52 |
| P/FCF Ratio | -0.69 |
| P/OCF Ratio | -0.69 |
Financial Position
Quoin Pharmaceuticals, Ltd. maintains a current ratio of 1.76, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.76 |
| Quick Ratio | 1.63 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -575.73 |
| Return on Assets (ROA) | -178.77 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Quoin Pharmaceuticals, Ltd.'s stock has declined approximately -75% over the past 52 weeks. The 50-day moving average sits at 5.64, while the 200-day moving average is 6.44.
| Beta (5Y) | N/A |
| 52-Week Price Change | -75% |
| 50-Day Moving Average | 5.64 |
| 200-Day Moving Average | 6.44 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -19.05M, while operating income came in at -19.15M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -19.15M |
| Pretax Income | -18.67M |
| Net Income | -18.67M |
| EBITDA | -19.05M |
| EBIT | -19.15M |
| Earnings Per Share (EPS) | -8.54 |
Balance Sheet
Total book value stands at 3.93M, with working capital of 5.02M providing operational flexibility.
| Cash & Cash Equivalents | 10.80M |
| Total Debt | N/A |
| Net Debt | -3.85M |
| Equity (Book Value) | 3.93M |
| Book Value Per Share | 0.06 |
| Working Capital | 5.02M |
Cash Flow
Quoin Pharmaceuticals, Ltd. produced -15.27M in operating cash flow over the past twelve months.
| Operating Cash Flow | -15.27M |
| Capital Expenditures | N/A |
| Free Cash Flow | -15.27M |
| FCF Per Share | -6.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -5.30 |
| FCF Yield | -144.32 |
Stock Splits
Quoin Pharmaceuticals, Ltd.'s most recent stock split took place on July 18, 2023 with a 12:1 split ratio.
| Last Split Date | 7/18/2023 |
| Split Ratio | 12:1 |
Scores
Quoin Pharmaceuticals, Ltd. posts an Altman Z-Score of 10.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.70 |